| Title |
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
|
|---|---|
| Published in |
Strahlentherapie und Onkologie, September 2014
|
| DOI | 10.1007/s00066-014-0737-7 |
| Pubmed ID | |
| Authors |
Henriette Golcher, Thomas B. Brunner, Helmut Witzigmann, Lukas Marti, Wolf-Otto Bechstein, Christiane Bruns, Henry Jungnickel, Stefan Schreiber, Gerhard G. Grabenbauer, Thomas Meyer, Susanne Merkel, Rainer Fietkau, Werner Hohenberger |
| Abstract |
In nonrandomized trials, neoadjuvant treatment was reported to prolong survival in patients with pancreatic cancer. As neoadjuvant chemoradiation is established for the treatment of rectal cancer we examined the value of neoadjuvant chemoradiotherapy in pancreatic cancer in a randomized phase II trial. Radiological staging defining resectability was basic information prior to randomization in contrast to adjuvant therapy trials resting on pathological staging. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 138 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 14% |
| Other | 15 | 11% |
| Student > Ph. D. Student | 14 | 10% |
| Student > Master | 12 | 9% |
| Student > Bachelor | 12 | 9% |
| Other | 28 | 20% |
| Unknown | 37 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 70 | 51% |
| Nursing and Health Professions | 5 | 4% |
| Agricultural and Biological Sciences | 3 | 2% |
| Biochemistry, Genetics and Molecular Biology | 2 | 1% |
| Social Sciences | 2 | 1% |
| Other | 8 | 6% |
| Unknown | 48 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2021.
All research outputs
#4,017,171
of 22,796,179 outputs
Outputs from Strahlentherapie und Onkologie
#29
of 748 outputs
Outputs of similar age
#44,365
of 252,196 outputs
Outputs of similar age from Strahlentherapie und Onkologie
#2
of 12 outputs
Altmetric has tracked 22,796,179 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 748 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,196 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.